WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include pharmaceutical, biotechnology and medical device companies. The Company operates in two segments: laboratory services and manufacturing. Laboratory services for pharmaceutical, biotechnology and medical device companies. Manufacturing segment services for producing advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials. In January 2008, the Company completed its acquisition of AppTec Laboratory Services, Inc.

Sandoz International GmbH engages in the development, production, marketing, and distribution of generic medicines, pharmaceutical and biotechnological active substances, and anti-infectives in Germany and internationally. It offers products for various therapeutic areas, including cardiovascular system, central nervous system, gastrointestinal system, muscle and skeletal system, hormone therapy, and respiratory system. The company’s product portfolio ranges from various application forms, such as oral solids through technologies, including inhalers or injectables to transdermal patches, implants, and biopharmaceutical follow-ons. It sells its products to wholesalers, pharmacies, hospitals, and other healthcare outlets. Sandoz International GmbH was founded in 1886 and is headquartered in Holzkirchen, Germany. The company has research and development, and production sites in Boucherville, Canada; Buenos Aires, Argentina; Cambe and Taboao da Serra, Brazil; Holzkirchen/Rudolstadt and Barleben, Germany; Kolshet, Kalwe, and Mahad, India; Kundl and Schaftenau, Austria; Menges and Ljubljana, Slovenia; Wilson, North Carolina; Broomfield, Colorado; Gebze and Syntex, Turkey; and Strykow, Poland. Sandoz International GmbH operates as a subsidiary of Novartis AG.

SciClone Pharmaceuticals, Inc. company was founded in 1989 and is headquartered in Foster City, California. SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. SciClone's products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma.

Martek Biosciences Corporation was founded in 1985 and is headquartered in Columbia, Maryland. Martek Biosciences Corporation engages in the innovation and development of nutritional products from microbial sources, including algae, fungi, and other microbes worldwide. Its products include life'sDHA, a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid) for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements, and animal feeds; and life'sARA, a vegetarian source of the omega-6 fatty acid ARA (arachidonic acid) for use in infant formula. The company also provides contract manufacturing services for the production of enzymes, specialty chemicals, vitamins, and agricultural specialty products. It sells oils containing fatty acids under the names of life'sDHA, DHASCO, Neuromins, ARASCO, and life'sARA. The company markets its nutritional oils primarily to the infant formula, pregnancy and nursing, food and beverage, dietary supplement, and animal feed markets.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

SeraCare Life Sciences, Inc. company was founded in 1984 and is headquartered in Milford, Massachusetts. SeraCare Life Sciences, Inc., a life sciences company, provides products and services to facilitate the discovery, development, and production of human and animal diagnostics, and therapeutics. The company’s portfolio includes diagnostic controls, plasma-derived reagents, and molecular biomarkers, as well as biobanking and contract research services. It operates in two segments, Diagnostic & Biopharmaceutical Products and BioServices. The Diagnostic & Biopharmaceutical Products segment provides controls and panels used for the evaluation and quality control of infectious disease tests in hospitals and clinical labs, blood banks, and in vitro diagnostic (IVD) manufacturing; and reagents and bioprocessing products, including biological materials for use in the research, development, and manufacture of human and animal diagnostics, therapeutics, and vaccines. This segment sells various controls and panels to hospital laboratories, independent clinical laboratories, public health laboratories, blood banks, IVD manufacturers, and government regulatory and research agencies; and reagents and bioprocessing products to diagnostic, pharmaceutical, and biotechnology product developers and manufacturers, as well as to research laboratories affiliated with government, academia, and private foundations.

Genitope is a drug development company in arrested development. It had hoped to find new ways to fight cancer with old weapons, but now it is just hoping to find a future. The company was researching immunotherapy treatments for cancer, using the body's own immune system to fight tumors. Genitope's leading drug candidate, MyVax, was a patient-specific immunotherapy that would specify the genetic makeup of the tumor, activate the patient's immune system to attack it, and cause no damage to cells other than the tumor. However, the drug did not do well in early clinical trials, and when the FDA requested additional trials for further review, Genitope chose to scrap the whole program.

Simcere Pharmaceutical Group was founded in 1995 and is headquartered in Nanjing, the People's Republic of China. Simcere Pharmaceutical Group is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. The Company has introduced a generic anti-stroke medication under the brand name Bicun, a 5-FU sustained release implant under the brand name Sinofuan and an anti-cancer medication under the brand name Endu. It manufactures and sells 45 principal pharmaceutical products and is the distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under its brand names. On May 5, 2008, it acquired 70% interest in Wuhu Zhong Ren Pharmaceutical Co., Ltd. (Wuhu Simcere Zhong Ren). On January 6, 2009, Simcere Pharmaceutical Group acquired the remaining 10% of interest of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd. (Shandong Simcere).

Unigene Laboratories, Inc. company was founded in 1980 and is based in Boonton, New Jersey. Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories, Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Shijiazhuang Pharmaceutical Group for research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH.

Ortho-McNeil, a subsidiary of gigantic healthcare company Johnson & Johnson, makes a variety of women's health and contraceptive products. A division of Ortho-McNeil-Janssen Pharmaceuticals, its women's health line is dominated by oral contraceptives, including Ortho-cyclen, Ortho-novum, and Modicon; other products include Ditropan for overactive bladder treatment and yeast infection drug Terazol. Sister company Ortho-McNeil Neurologics was created to hold Ortho-McNeil's central nervous system drugs, including epilepsy treatment Topamax, pain management drug Ultracet, Alzheimer's treatments, and migraine remedies, allowing the company to focus strictly on women's health.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.